Shares of Guardant Health (NASDAQ: GH) rose nearly 108% last year, according to data provided by S&P Global market Intelligence. In its first full year on the market, the liquid biopsy specialist easily outperformed the 28.8% gain of the S&P 500 in 2019.
While the stock suffered from hype and the volatility associated with it, operating results largely support the company's $7.3 billion market valuation. In fact, Guardant Health is growing so quickly that it raised full-year 2019 financial guidance in each of its last four quarterly updates.
Image source: Getty Images.